-
FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury
Wednesday, May 26, 2021 - 2:24pm | 305Read More...The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc’s (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary cholangitis (PBC) patients with advanced cirrhosis. PBC is a rare, chronic disease affecting the ducts in the liver that...
-
Conatus Pharmaceuticals Surges 25% Following Positive Results In Phase 2 Study
Wednesday, January 6, 2016 - 9:45am | 300Read More...Shares of Conatus Pharmaceuticals Inc (NASDAQ: CNAT), a small-cap biopharmaceutical company focused on developing medicines to treat liver diseases, were trading higher by 25 percent at $3.61 early Wednesday morning. Conatus Pharmaceuticals announced after Tuesday's market close that a three-month...
